These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1310219)

  • 61. Attenuation of blood pressure increases in Dahl salt-sensitive rats by exercise.
    Shepherd RE; Kuehne ML; Kenno KA; Durstine JL; Balon TW; Rapp JP
    J Appl Physiol Respir Environ Exerc Physiol; 1982 Jun; 52(6):1608-13. PubMed ID: 7107471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake.
    Sakai RR; McEwen BS; Fluharty SJ; Ma LY
    Kidney Int; 2000 Apr; 57(4):1337-45. PubMed ID: 10760064
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mineralocorticoids, salt, hypertension: effects on the heart.
    Young MJ; Funder JW
    Steroids; 1996 Apr; 61(4):233-5. PubMed ID: 8733007
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An ACTH/MSH(4-9) analog counteracts the behavioral effects of a mineralocorticoid receptor antagonist.
    Oitzl MS; Josephy M; Spruijt BM
    Pharmacol Biochem Behav; 1993 Feb; 44(2):447-50. PubMed ID: 8383343
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exogenous 25-hydroxycholecalciferol does not attenuate salt-induced hypertension.
    Thierry-Palmer M; Tewolde TK; Wang M; Carlyle KS; Forté C; Bayorh MA; Emmett NL; Williams EF
    J Steroid Biochem Mol Biol; 1998 Nov; 67(3):193-9. PubMed ID: 9879978
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects.
    Sutanto W; de Kloet ER
    Med Res Rev; 1991 Nov; 11(6):617-39. PubMed ID: 1662327
    [No Abstract]   [Full Text] [Related]  

  • 67. Mineralocorticoid antagonist inhibits stress-induced blood pressure response after repeated daily warming.
    Van den Berg DT; de Jong W; de Kloet ER
    Am J Physiol; 1994 Dec; 267(6 Pt 1):E921-6. PubMed ID: 7810635
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Brain nitric oxide synthase messenger RNA in central mineralocorticoid hypertension.
    Takeda Y; Miyamori I; Yoneda T; Furukawa K; Inaba S; Takeda R; Mabuchi H
    Hypertension; 1997 Oct; 30(4):953-6. PubMed ID: 9336399
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modulation of blood pressure in the Dahl SS/jr rat by embryo transfer.
    Kubisch HM; Mathialagan S; Gómez-Sánchez EP
    Hypertension; 1998 Jan; 31(1 Pt 2):540-5. PubMed ID: 9453359
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antihypertensive effects of an aromatase inhibitor in inbred salt-sensitive rats.
    Griffing GT; Melby JC; Holbrook M; Johnston ON
    Hypertension; 1991 Jun; 17(6 Pt 1):771-5. PubMed ID: 2045138
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats.
    Francis J; Beltz T; Johnson AK; Felder RB
    Am J Physiol Regul Integr Comp Physiol; 2003 Dec; 285(6):R1402-9. PubMed ID: 14615404
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Brain corticosteroid receptors and regulation of arterial blood pressure.
    van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
    J Hypertens Suppl; 1989 Dec; 7(6):S202-3. PubMed ID: 2561139
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Central effects of mineralocorticoids on blood pressure: new answers, new questions.
    Funder JW
    J Hypertens; 2002 Sep; 20(9):1715-6. PubMed ID: 12195108
    [No Abstract]   [Full Text] [Related]  

  • 74. Hypertensive mechanisms associated with centrally administered aldosterone in dogs.
    Kageyama Y; Bravo EL
    Hypertension; 1988 Jun; 11(6 Pt 2):750-3. PubMed ID: 3391682
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of central mineralocorticoid receptors in cardiovascular disease.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    Curr Hypertens Rep; 2001 Jun; 3(3):263-9. PubMed ID: 11353578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of the mineralocorticoid receptor in rat heart with the aid of two new spirolactone derivatives.
    Agarwal MK; Kalimi M
    Biochem Med Metab Biol; 1989 Feb; 41(1):36-45. PubMed ID: 2540779
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Variable mapping of structure-activity relationships: application to 17-spirolactone derivatives with mineralocorticoid activity.
    Grassy G; Trape P; Bompart J; Calas B; Auzou G
    J Mol Graph; 1995 Dec; 13(6):356-67. PubMed ID: 8820304
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mineralocorticoid radioreceptor assay: application to adrenal-regeneration hypertension.
    Gomez-Sanchez C; Holland OB; Murry BA
    Life Sci; 1977 Oct; 21(7):989-96. PubMed ID: 22013
    [No Abstract]   [Full Text] [Related]  

  • 79. Mineralocorticoid modulation of central control of blood pressure.
    Gómez Sánchez EP
    Steroids; 1995 Jan; 60(1):69-72. PubMed ID: 7792819
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rat lung possesses the mineralocorticoid receptor.
    Agarwal MK; Mirshahi M
    Biochem Biophys Res Commun; 1992 Mar; 183(2):405-10. PubMed ID: 1312828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.